Bayer’s Purchase Of Schering AG Creates $4.5 Bil. Diagnostics Company
This article was originally published in The Gray Sheet
Executive Summary
Bayer's purchase of Schering AG will add imaging agents to the firm's diagnostics portfolio and boost testing-related revenue by roughly two-thirds to $4.5 bil. annually
You may also be interested in...
Schering/Epix’ Vasovist
Formal appeal of vascular imaging agent Vasovist "approvable" letters is filed June 30 with FDA, seeking final agency clearance. The appeal "underscores our confidence in the clinical profile and benefits of Vasovist," developer Epix states. The most recent of two approvable letters issued to date for the magnetic resonance angiography agent, received last November, indicated that at least one additional trial, and a re-read of images obtained in certain of the previously completed Phase III trials, would be required prior to approval. The company also requests that an advisory committee be used as part of the appeal process. Vasovist (gadofosveset) marketing partner Schering AG was recently acquired by Bayer (1"The Gray Sheet" June 26, 2006, p. 13)...
Schering/Epix’ Vasovist
Formal appeal of vascular imaging agent Vasovist "approvable" letters is filed June 30 with FDA, seeking final agency clearance. The appeal "underscores our confidence in the clinical profile and benefits of Vasovist," developer Epix states. The most recent of two approvable letters issued to date for the magnetic resonance angiography agent, received last November, indicated that at least one additional trial, and a re-read of images obtained in certain of the previously completed Phase III trials, would be required prior to approval. The company also requests that an advisory committee be used as part of the appeal process. Vasovist (gadofosveset) marketing partner Schering AG was recently acquired by Bayer (1"The Gray Sheet" June 26, 2006, p. 13)...
Siemens Buys Bayer Diagnostics, Becomes Third Largest IVD Company
Siemens' purchase of Bayer's diagnostics division, under a $5.3 bil. deal announced June 29, will make it the third largest player in the in vitro diagnostics market behind Roche and Abbott